Patents by Inventor Eric Toone
Eric Toone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9649832Abstract: A polymerizable composition includes at least one monomer, a photoinitiator capable of initiating polymerization of the monomer when exposed to light, and a phosphor capable of producing light when exposed to radiation (typically X-rays). The material is particularly suitable for bonding components at ambient temperature in situations where the bond joint is not accessible to an external light source. An associated method includes: placing a polymerizable adhesive composition, including a photoinitiator and energy converting material, such as a down-converting phosphor, in contact with at least two components to be bonded to form an assembly; and, irradiating the assembly with radiation at a first wavelength, capable of conversion (down-conversion by the phosphor) to a second wavelength capable of activating the photoinitiator, to prepare items such as inkjet cartridges, wafer-to-wafer assemblies, semiconductors, integrated circuits, and the like.Type: GrantFiled: January 9, 2015Date of Patent: May 16, 2017Assignees: Immunolight, LLC, Duke UniversityInventors: Zakaryae Fathi, James Clayton, Harold Walder, Frederic A. Bourke, Jr., Ian Stanton, Jennifer Ayres, Joshua T. Stecher, Michael Therien, Eric Toone, Dave Gooden, Mark Dewhirst, Joseph A. Herbert, Diane Fels, Katherine S. Hansen
-
Publication number: 20150246521Abstract: A polymerizable composition includes at least one monomer, a photoinitiator capable of initiating polymerization of the monomer when exposed to light, and a phosphor capable of producing light when exposed to radiation (typically X-rays). The material is particularly suitable for bonding components at ambient temperature in situations where the bond joint is not accessible to an external light source. An associated method includes: placing a polymerizable adhesive composition, including a photoinitiator and energy converting material, such as a down-converting phosphor, in contact with at least two components to be bonded to form an assembly; and, irradiating the assembly with radiation at a first wavelength, capable of conversion (down-conversion by the phosphor) to a second wavelength capable of activating the photoinitiator, to prepare items such as inkjet cartridges, wafer-to-wafer assemblies, semiconductors, integrated circuits, and the like.Type: ApplicationFiled: January 9, 2015Publication date: September 3, 2015Applicants: lmmunolight, LLC, Duke UniversityInventors: Zakaryae FATHI, James CLAYTON, Harold WALDER, Frederic A. BOURKE, JR., Ian STANTON, Jennifer AYRES, Joshua T. STECHER, Michael THERIEN, Eric TOONE, Dave GOODEN, Mark DEWHIRST, Joseph A. HERBERT, Diane FELS, Katherine S. HANSEN
-
Patent number: 9023249Abstract: A polymerizable composition includes at least one monomer, a photoinitiator capable of initiating polymerization of the monomer when exposed to light, and a phosphor capable of producing light when exposed to radiation (typically X-rays). The material is particularly suitable for bonding components at ambient temperature in situations where the bond joint is not accessible to an external light source. An associated method includes: placing a polymerizable adhesive composition, including a photoinitiator and energy converting material, such as a down-converting phosphor, in contact with at least two components to be bonded to form an assembly; and, irradiating the assembly with radiation at a first wavelength, capable of conversion (down-conversion by the phosphor) to a second wavelength capable of activating the photoinitiator, to prepare items such as inkjet cartridges, wafer-to-wafer assemblies, semiconductors, integrated circuits, and the like.Type: GrantFiled: May 6, 2011Date of Patent: May 5, 2015Assignees: Immunolight, LLC, Duke UniversityInventors: Zakaryae Fathi, James Clayton, Harold Walder, Frederic A. Bourke, Jr., Ian Stanton, Jennifer Ayres, Joshua T. Stecher, Michael Therien, Eric Toone, Dave Gooden, Mark Dewhirst, Joseph A. Herbert, Diane Fels, Katherine S. Hansen
-
Patent number: 8907109Abstract: Psoralen compounds of Formula (I): wherein (N+ Aryl) is a member selected from the group consisting of nitrogen containing aromatic heterocycles of formulae (i)-(iii): wherein Z is a group of formula: wherein R is C1-C30 hydrocarbyl, which may be linear, branched or cyclic and contains from 1 to 15 carbon-carbon double bonds, which may be conjugated or unconjugated with one another or may include an aryl ring, and may contain one or more substituents; R1 is hydrogen, aryl, heteroaryl, alkyl, cycloalkyl, heterocyclyl, alkenyl, alkynyl, alkene-aryl, alkene-heteroaryl, alkene-heterocyclyl, alkene-cycloalkyl, fused cycloalkylaryl, fused cycloalkylheteroaryl, fused heterocyclylaryl, fused heterocyclyheteroaryl, alkylene-fused cycloalkylaryl, alkylene-fused cycloalkylheteroaryl, alkylene-fused heterocyclylaryl, alkylene-fused heterocyclyheteroaryl; n is an integer from 1 to 8 and X is a pharmaceutically acceptable counter ion; and their use in methods for the treatment of a cell proliferatType: GrantFiled: January 11, 2013Date of Patent: December 9, 2014Assignees: Immunolight, LLC, Duke UniversityInventors: Eric Toone, David Gooden, Tuan Vo-Dinh, Frederic A. Bourke, Jr.
-
Patent number: 8791275Abstract: Psoralen compounds of Formula (I): wherein (N+ Aryl) is a member selected from the group consisting of nitrogen containing aromatic heterocycles of formulae (i)-(iii): wherein Z is a group of formula: wherein R is C1-C30 hydrocarbyl, which may be linear, branched or cyclic and contains from 1 to 15 carbon-carbon double bonds, which may be conjugated or unconjugated with one another or may include an aryl ring, and may contain one or more substituents; R1 is hydrogen, aryl, heteroaryl, alkyl, cycloalkyl, heterocyclyl, alkenyl, alkynyl, alkene-aryl, alkene-heteroaryl, alkene-heterocyclyl, alkene-cycloalkyl, fused cycloalkylaryl, fused cycloalkylheteroaryl, fused heterocyclylaryl, fused heterocyclyheteroaryl, alkylene-fused cycloalkylaryl, alkylene-fused cycloalkylheteroaryl, alkylene-fused heterocyclylaryl, alkylene-fused heterocyclyheteroaryl; n is an integer from 1 to 8 and X is a pharmaceutically acceptable counter ion; and their use in methods for the treatment of a cell proliferatType: GrantFiled: January 11, 2013Date of Patent: July 29, 2014Assignees: Duke University, Immunolight, LLCInventors: Eric Toone, David Gooden, Tuan Vo-Dinh, Frederic A. Bourke, Jr.
-
Patent number: 8383836Abstract: Psoralen compounds of Formula (I): wherein (N+ Aryl) is a member selected from the group consisting of nitrogen containing aromatic heterocycles of formulae (i)-(iii): wherein Z is a group of formula: wherein R is C1-C30 hydrocarbyl, which may be linear, branched or cyclic and contains from 1 to 15 carbon-carbon double bonds, which may be conjugated or unconjugated with one another or may include an aryl ring, and may contain one or more substituents; R1 is hydrogen, aryl, heteroaryl, alkyl, cycloalkyl, heterocyclyl, alkenyl, alkynyl, alkene-aryl, alkene-heteroaryl, alkene-heterocyclyl, alkene-cycloalkyl, fused cycloalkylaryl, fused cycloalkylheteroaryl, fused heterocyclylaryl, fused heterocyclyheteroaryl, alkylene-fused cycloalkylaryl, alkylene-fused cycloalkylheteroaryl, alkylene-fused heterocyclylaryl, alkylene-fused heterocyclyheteroaryl; n is an integer from 1 to 8 and X is a pharmaceutically acceptable counter ion; and their use in methods for the treatment of a cell proliferatType: GrantFiled: April 20, 2010Date of Patent: February 26, 2013Assignees: Duke University, Immunolight, LLCInventors: Eric Toone, David Gooden, Tuan Vo-Dinh, Frederic A. Bourke, Jr.
-
Publication number: 20120089180Abstract: A polymerizable composition includes at least one monomer, a photoinitiator capable of initiating polymerization of the monomer when exposed to light, and a phosphor capable of producing light when exposed to radiation (typically X-rays). The material is particularly suitable for bonding components at ambient temperature in situations where the bond joint is not accessible to an external light source. An associated method includes: placing a polymerizable adhesive composition, including a photoinitiator and energy converting material, such as a down-converting phosphor, in contact with at least two components to be bonded to form an assembly; and, irradiating the assembly with radiation at a first wavelength, capable of conversion (down-conversion by the phosphor) to a second wavelength capable of activating the photoinitiator, to prepare items such as inkjet cartridges, wafer-to-wafer assemblies, semiconductors, integrated circuits, and the like.Type: ApplicationFiled: May 6, 2011Publication date: April 12, 2012Applicants: Duke University, Immunolight, LLCInventors: Zakaryae Fathi, James Clayton, Harold Walder, Frederic A. Bourke, JR., Ian Stanton, Jennifer Ayres, Joshua T. Stecher, Michael Therien, Eric Toone, Dave Gooden, Mark Dewhirst, Joseph A. Herbert, Diane Fels, Katherine S. Hansen
-
Publication number: 20100266621Abstract: Psoralen compounds of Formula (I): wherein (N+ Aryl) is a member selected from the group consisting of nitrogen containing aromatic heterocycles of formulae (i)-(iii): wherein Z is a group of formula: wherein R is C1-C30 hydrocarbyl, which may be linear, branched or cyclic and contains from 1 to 15 carbon-carbon double bonds, which may be conjugated or unconjugated with one another or may include an aryl ring, and may contain one or more substituents; R1 is hydrogen, aryl, heteroaryl, alkyl, cycloalkyl, heterocyclyl, alkenyl, alkynyl, alkene-aryl, alkene-heteroaryl, alkene-heterocyclyl, alkene-cycloalkyl, fused cycloalkylaryl, fused cycloalkylheteroaryl, fused heterocyclylaryl, fused heterocyclyheteroaryl, alkylene-fused cycloalkylaryl, alkylene-fused cycloalkylheteroaryl, alkylene-fused heterocyclylaryl, alkylene-fused heterocyclyheteroaryl; n is an integer from 1 to 8 and X is a pharmaceutically acceptable counter ion; and their use in methods for the treatment of a cell proliferatType: ApplicationFiled: April 20, 2010Publication date: October 21, 2010Applicants: Duke University, Immunolight, LLCInventors: Eric Toone, David Gooden, Tuan Vo-Dinh, Frederic A. Bourke, JR.
-
Publication number: 20100094060Abstract: C-nitroso compound releases nitroxyl ion in blood in a second order reaction.Type: ApplicationFiled: April 16, 2008Publication date: April 15, 2010Applicant: Duke UniversityInventors: Eric Toone, David M. Gooden
-
Patent number: 7598092Abstract: A cantilever array can be positioned adjacent a surface in the presence of a sample. The cantilever array includes a plurality of cantilevers having one member of a specific binding pair thereon. The surface includes the other member of a specific binding pair. Binding between the members of the binding pair on the cantilevers and the surface can be detected. The presence, absence and/or concentration of a member of the specific binding pair in the sample can be detected based on the detected binding between the specific binding pair member on the cantilevers and the specific binding pair member on the surface.Type: GrantFiled: June 7, 2007Date of Patent: October 6, 2009Inventors: Eric Toone, Piotr Marszalek, Robert L. Clark, Phil Snyder
-
Publication number: 20080090259Abstract: A cantilever array can be positioned adjacent a surface in the presence of a sample. The cantilever array includes a plurality of cantilevers having one member of a specific binding pair thereon. The surface includes the other member of a specific binding pair. Binding between the members of the binding pair on the cantilevers and the surface can be detected. The presence, absence and/or concentration of a member of the specific binding pair in the sample can be detected based on the detected binding between the specific binding pair member on the cantilevers and the specific binding pair member on the surface.Type: ApplicationFiled: June 7, 2007Publication date: April 17, 2008Inventors: Eric Toone, Piotr Marszalek, Robert Clark, Phil Snyder
-
Publication number: 20070258942Abstract: A C-nitroso compound having a molecular weight ranging from 225 to 1,000 (from 225 to 600 for oral administration) on a monomeric basis wherein a nitroso group is attached to a tertiary carbon, which is obtained by nitrosylation of a carbon acid having a pKa less than about 25, is useful as an NO donor. When the compound is obtained from a carbon acid with a pKa less than about 10, it provides vascular relaxing effect when used at micromolar concentrations and this activity is potentiated by glutathione to be obtained at nanomolar concentrations. When the compound is obtained from a carbon acid with a pKa ranging from about 15 to about 20, vascular relaxing effect is obtained at nanomolar concentrations without ghitathione. In another embodiment, a biocompatible polymer incorporates a C-nitroso moiety.Type: ApplicationFiled: July 10, 2007Publication date: November 8, 2007Applicant: Duke UniversityInventors: Jonathan Stamler, Eric Toone
-
Publication number: 20070254920Abstract: This invention relates to novel homotopic prodrugs and medicaments and methods for their preparation, testing and use. In one embodiment, the homotopic prodrug has the general formula wherein is a biologically-active moiety comprising a carboxylic acid functional group, and Rb is a homotopically-symmetrical alcohol bonded to the biologically-active moiety through the carboxylic acid functional group to form an ester linkage, as well as optical isomers, enantiomers, pharmaceutically acceptable salts, biohydrolyzable amides, esters, and imides thereof and combinations thereof.Type: ApplicationFiled: April 26, 2006Publication date: November 1, 2007Applicant: Aerie Pharmaceuticals, Inc.Inventors: Mitchell deLong, Jill McFadden, Susan Royalty, Eric Toone, Jeffrey Yingling
-
Publication number: 20070191478Abstract: Treatment of pulmonary disorders associated with hypoxemia and/or smooth muscle constriction and/or inflammation comprises administering into the lungs as a gas a compound with an NO group which does not form NO2/NOx in the presence of oxygen or reactive oxygen species at body temperature. Treatment of cardiac and blood disorders, e.g., angina, myocardial infarction, heart failure, hypertension, sickle cell disease and clotting disorders, comprises administering into the lungs as a gas, a compound which reacts with cysteine in hemoglobin and/or dissolves in blood and has an NO group which is bound in said compound so that it does not form NO2/NOx in the presence of oxygen or reactive oxygen species at body temperature. Exemplary of the compound administered in each case is ethyl nitrite. Treatment of patient in need of improved oxygenation, blood flow of and/or thinning of blood comprises providing in the patient a therapeutic amount of red blood cells loaded with nitrosylated hemoglobin.Type: ApplicationFiled: September 20, 2005Publication date: August 16, 2007Inventors: Jonathan Stamler, Eric Toone, Andrew Gow
-
Publication number: 20070088435Abstract: Disclosed are novel polymers derivatized with at least one —NOx group per 1200 atomic mass unit of the polymer. X is one or two. In one embodiment, the polymer is an S-nitrosylated polymer and is prepared by reacting a polythiolated polymer with a nitrosylating agent under conditions suitable for nitrosylating free thiol groups. The polymers of the present invention can be used to coat medical devices to deliver nitric oxide in vivo to treatment sites.Type: ApplicationFiled: August 7, 2006Publication date: April 19, 2007Inventors: Jonathan Stamler, Eric Toone, Richard Stack
-
Publication number: 20060217439Abstract: Disclosed are novel NO-releasing compounds which comprise a stabilized S-nitrosyl group and a free alcohol or a free thiol group. Also disclosed is a method of preparing the NO-releasing compounds. The method comprises reacting a polythiol or a thioalcohol with a nitrosylating agent. Also disclosed are medical devices coated with the disclosed compounds, methods of delivering NO to treatments sites in a subject by utilizing the medical devices and methods of sterilizing surfaces.Type: ApplicationFiled: March 14, 2006Publication date: September 28, 2006Inventors: Eric Toone, Jonathan Stamler
-
Publication number: 20060194820Abstract: A reactive oxygen generating enzyme inhibitor with NO donor bioactivity, e.g., nitrated allopurinol, is useful to treat heart failure, stable angina, ischemic disorder, ischemic reperfusion injury, atherosclerosis, sickle cell disease, diabetes, Alzheimer's disease, Parkinson's disease, ALS and asthma and to obtain proper contraction of heart, skeletal and smooth muscle.Type: ApplicationFiled: May 10, 2006Publication date: August 31, 2006Applicants: Duke University, Johns Hopkins UniversityInventors: Jonathan Stamler, Eric Toone, Joshua Hare
-
Publication number: 20060153931Abstract: NO, NO donor or prodrug that causes formation of nitrosothiol in tissue optionally in combination with lidocaine is topically applied to pedicle of a pedicle flap or other source of blood supply to prevent necrosis in pedicle flap or in any microvascular surgery. Composition containing drug is formulated with nitrosylated polythiolated cyclodextrin to improve drug delivery.Type: ApplicationFiled: December 2, 2002Publication date: July 13, 2006Inventors: Jonathan Stamler, Michael Zenn, Eric Toone
-
Publication number: 20060135609Abstract: The present invention relates generally to ophthamological drugs. More specifically, the inventon relates to a method of modifying (derivatizing) ophthamological drugs so as to increase their penetration through the cornea. The invention also relates to drugs modified (derivatized) in accordance with the instant method and to the use of same in treating conditions associated with elevated intraocular pressure, particularly, glaucoma.Type: ApplicationFiled: October 21, 2005Publication date: June 22, 2006Applicant: Duke UniversityInventors: Eric Toone, David Epstein, Pratap Challa, Phillip Snyder, Xin Chen, Mitchell deLong
-
Publication number: 20050239807Abstract: A reactive oxygen generating enzyme inhibitor with NO donor bioactivity, e.g., nitrated allopurinol, e.g., 1,5-bis(3-nitrooxypropyyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidine-4-one is useful to treat heart failure, stable angina, ischemic disorder, ischemic reperfusion injury, atherosclerosis, sickle cell disease, diabetes, Alzheimer's disease, Parkinson's disease, ALS and asthma and to obtain proper contraction of heart, skeletal and smooth muscle. Where the disorder is heart failure, administration of the enzyme inhibitor mediates amelioration of acute coronary symptoms and/or myocardial infarction.Type: ApplicationFiled: April 23, 2004Publication date: October 27, 2005Inventors: Jonathan Stamler, Eric Toone, Joshua Hare